High Prevalence of Hospital Infections and Demand for Anti-infective Drugs to Drive Hospital-Acquired Infection Therapeutics Market USD 4.1 Billion by 2020

The global hospital-acquired infection therapeutics market is estimated to reach USD 4.1 Billion in 2020, growing at a CAGR of 5.1% from 2016 to 2020, according to a new market research report Hospital-Acquired Infection Therapeutics Market – Global HAI Therapeutic Drugs, Indication and Pipeline Analysis and Forecast 2013-2020, published by iHealthcareAnalyst, Inc.

Visit the Hospital-Acquired Infection Therapeutics Market – Global HAI Therapeutic Drugs, Indication and Pipeline Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/hospital-infection-therapeutics-market/

Hospital-acquired or hospital-associated infections (HAI) or nosocomial infections are contracted from the environment or staff of a healthcare facility. It can also spread in the hospital environment, nursing home environment, rehabilitation facility, clinic, or other clinical settings. HAIs are caused by viral, bacterial, and fungal pathogens; the most common types are bloodstream infection (BSI), pneumonia (e.g., ventilator-associated pneumonia [VAP]), urinary tract infection (UTI), and surgical site infection (SSI). While antibiotic drugs to treat diseases caused by gram-positive MRSA are available, few effective drugs are available for Acinetobacter bacteria that are evolving and becoming immune to existing antibiotics. The global hospital-acquired infection therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (antibacterial, antifungal and antiviral drugs), clinical pipeline analysis of phase 1, 2 and 3 drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), indications (blood stream infections, gastrointestinal disorders, HAP, SSIs, UTIs, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

The global hospital-acquired infection therapeutics market is segmented as:

1. Drug Type
1.1. Antibacterial Drugs
1.2. Antifungal Drugs
1.3. Antiviral Drugs

2. Pipeline Analysis
2.1. Amikacin Inhale
2.2. CAZ AVI (Ceftazidime/Avibactum)
2.3. Ceftolozane/Tazobactam
2.4. Dalvance (Dalbavancin)
2.5. Delafloxacin (RX-3341)
2.6. Eravacycline (TP-434)
2.7. MK-3415A
2.8. Oritavancin
2.9. Plazomicin
2.10. Surotomycin (CB-315)
2.11. Tedizolid (TR-701)

3. Indication Type
3.1. Bloodstream Infections
3.2. Gastrointestinal Disorders
3.3. Hospital-Acquired Pneumonia (HAP)
3.4. Surgical Site Infections (SSIs)
3.5. Urinary Tract Infections (UTIs)
3.6. Other Hospital Infections

4. Geography (Region, Country)
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC)
4.5. Rest of the World

5. Company Profiles
5.1. Actavis plc
5.2. AstraZeneca plc
5.3. Bayer AG
5.4. Bristol-Myers Squibb Company
5.5. Cubist Pharmaceuticals, Inc.
5.6. GlaxoSmithKline plc
5.7. Johnson & Johnson
5.8. Merck & Co., Inc.
5.9. Pfizer, Inc.
5.10. Sanofi SA

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
http://www.ihealthcareanalyst.com

This release was published on openPR.